Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.32 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795774 | 0.91 | ACLY (0.33) | ACLYCA1CA2DCLRE1BRECQL | |
| SCHEMBL28058729 | 0.91 | PDK2 (0.34) | CA1CA2DCLRE1BSSTR5SGK1 | |
| SCHEMBL3457034 | 0.91 | ACLY (0.35) | ACLYCA1CA2DCLRE1BRECQL | |
| SCHEMBL1798784 | 0.91 | GPR52 (0.35) | CA1CA2SSTR5 | |
| SCHEMBL1801082 | 0.91 | ACLY (0.33) | ACLYCA1CA2DCLRE1BRECQL | |
| SCHEMBL1799389 | 0.89 | NPC1 (0.36) | CA1CA2LTB4RLTB4R2 | |
| SCHEMBL12274098 | 0.88 | RXRB (0.41) | CA1CA2RECQLPKM | |
| SCHEMBL29385555 | 0.88 | RXRB (0.41) | CA1CA2RECQLPKM | |
| SCHEMBL362701 | 0.88 | RXRB (0.41) | CA1CA2RECQLPKM | |
| SCHEMBL29397265 | 0.88 | RXRB (0.41) | CA1CA2RECQLPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748155-B1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-9247740-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-9247740-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| EP-1932836-B1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND HARMFUL ORGANISM-CONTROLLING AGENT | NISSAN CHEMICAL IND LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013026931-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026695-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | CHRM1, CHRM3, CHRM2 | ACLY 351/4885CA1 1012/4885CA2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.